Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Top Cited Papers
- 30 November 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 11 (12), 909-922
- https://doi.org/10.1038/nrd3845
Abstract
In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.Keywords
This publication has 101 references indexed in Scilit:
- Large-scale prediction and testing of drug activity on side-effect targetsNature, 2012
- How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?British Journal of Pharmacology, 2011
- Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic riskCardiovascular Research, 2011
- Genome-wide association study of PR intervalNature Genetics, 2010
- The future of endocannabinoid-oriented clinical research after CB1 antagonistsPsychopharmacology, 2009
- PDE4 inhibitors: current statusBritish Journal of Pharmacology, 2008
- Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?British Journal of Pharmacology, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- In silico pharmacology for drug discovery: applications to targets and beyondBritish Journal of Pharmacology, 2007
- How many drug targets are there?Nature Reviews Drug Discovery, 2006